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ABSTRACT 
Objective: The objective of the present study was to formulate niosomal formulations of benazepril hydrochloride in an attempt to overcome the 
hurdles associated with itʼs poor oral absorption. 
Methods: Nine formulations were prepared with various ratios of sorbitan monostearate (span 60), sorbitan monopalmitate (span 40) and 
polyoxyethylene 2 stearyl ether (brij 72) as non-ionic surfactants, cholesterol as a stabilizing agent and soya lecithin as a charge imparting agent. 
Then, they were characterized for vesicle size, polydispersity (PDI), entrapment efficiency (EE %), release profile, zeta (ζ) potential and 
transmission electron microscopy (TEM). 
Results: Niosomal formulations exhibited an efficient entrapment range between (80.4-97.8) percent, vesicles size analyses revealed the formation 
of homogenously dispersed vesicles having a size range of (3.9±1.7-8.72±4.4) micrometers. The in vitro release studies revealed that all 
formulations displayed sustained release in comparison with the pure drug. Formulations prepared with span 60 and span 40 possessed adequate 
stability according to zeta potential analysis, whereas brij 72 failed the test and possessed inadequate zeta potential range. TEM images of the 
optimized formulations (F7 and F8) have confirmed the formation of vesicles with spherical shapes. 
Conclusion: Based on the study results, niosomal formulations seem to be attractive alternatives to conventional delivery for benazepril hydrochloride. 
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Vesicular systems have drawn attention as promising carriers that are 
widely investigated for controlled delivery of pharmaceuticals to 
enhance their bioavailability, selectivity, and minimize toxicity. Due to 
their unique structure as a lamella consisting of amphiphiles, they can 
accommodate both the hydrophilic and hydrophobic molecules within 
their aqueous core and lipid bilayers, respectively. These comprise of 
liposomes, niosomes, ethosomes, transferosomes and bilosomes [1]. 
While liposomes require high formulation cost and are highly 
susceptible to oxidation. Niosomes, on the other hand, are cheap and 
stable over a longer period of time in different conditions. Niosomes are 
made up of non-ionic surfactants and cholesterol. Surfactants commonly 
employed include polyoxyethylene fatty acid esters (tweens), sorbitan 
fatty acid esters (spans), alkyl ethers, and polyoxyethylene alkyl ethers 
(brijs) [2]. Niosomal formulations are able to traverse the intestinal 
epithelium through different routes as transcellular, paracellular 
transport and/or nonspecific uptake mechanisms (by M-cells and 
intestinal epithelial cells). Therefore, they have been extensively studied 
in improving oral bioavailability of poorly absorbed drugs [3]. 
Benazepril hydrochloride is an angiotensin-converting enzyme inhibitor. 
It is used in the management of hypertension and heart failure. The 
problem with the drug is poor oral absorption (37%) [4]. Consequently, 
this arises the need for developing novel vesicular carriers to improve 
it's oral bioavailability. The aim of the present work was to formulate 
niosomal formulations of benazepril hydrochloride using different non-
ionic surfactants, cholesterol as a membrane stabilizing agent and soya 
lecithin as a charge imparting agent. Formulations were in vitro 
characterized for vesicle size, polydispersity (PDI), zeta (ζ) potential, 
entrapment efficiency (EE %) and release behaviour.  
MATERIALS AND METHODS 
Materials 
Benazepril HCL and brij 72 (polyoxyethylene 2 stearylether) were 
obtained from Baoji Guokang Bio-Technology Co., Ltd, China. Cholesterol 
and soya lecithin were obtained from M/S Provizer Pharma, India. Span 
60 (sorbitan monostearate) and span 40 (sorbitan monopalmitate) were 
obtained from Sinopharm Chemical Reagent Co., Ltd., China. Dialysis 
bags were obtained from Schuchardt München, Germany. 
Methodology 
Preparation of niosomes 
Niosomal formulations were prepared using the conventional thin 
film hydration method. Firstly, surfactant and cholesterol in 
amounts given in table (1) were dissolved in 10 ml chloroform and 
added into a 100–ml flask of the rotary evaporator (R-210, Buchi). 
Then, chloroform was allowed to evaporate under reduced pressure 
and gentle rotation in a water bath thermo-stated at 60±2 °C until 
observing a thin lipid layer. An aqueous phase containing 10 mg 
benazepril HCL dissolved in 10 ml distilled water was added to the 
lipid phase at atmospheric pressure under gentle rotation in a water 
bath at 60±2 °C for 60 min, followed by sonication in a bath 
sonicator (SB 25-12 DTDN) for additional 60 min. Afterwards, the 
obtained formulations were stored in 4 °C for further analysis [5]. 
Characterization of benazepril hydrochloride niosomes 
Vesicle size and polydispersity index (PDI) 
The prepared formulations were observed under an optical 
microscope (Novex, Holland) to confirm vesicles formation. 
Microphotographs were taken by a camera attached to the 
microscope. Then, further analysis using image j software was 
undertaken to measure the mean diameter and polydispersity index 
(PDI) for vesicles that lie within the micro size range [6]. 
Measurements were carried out in triplicate for each formulation 
and presented as the average ±standard deviation (SD). 
Entrapment efficiency (EE %) 
Niosomal formulations were centrifuged at 14000 round per minute 
(rpm) for 90 min at 4 °C in a cooling centrifuge (Hermle labortechnik, 
Germany) to separate the free drug from the entrapped drug. The 
obtained clear supernatant fraction was then analyzed 
spectrophotometrically at 241 nm [7].  
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The percent entrapment efficiency was calculated using the below 
equation [8]: 
EE %= Total drug−free drug 
total drug 
 * 100 
 
Table 1: The composition of niosomal formulations 
Formulation Benazepril HCl Span 60 Span 40  Brij 72 Cholesterol Soya lecithin 
F1 10 mg 400 mg   100 mg  
F2 10 mg  400 mg  100 mg  
F3 10 mg   400 mg 100 mg  
F4 10 mg 400 mg   400 mg  
F5 10 mg  400 mg  400 mg  
F6 10 mg   400 mg 400 mg  
F7 10 mg 400 mg   400 mg 50 mg 
F8 10 mg  400 mg  400 mg 50 mg 
F9 10 mg   400 mg 400 mg 50 mg 
Formulations (F1-F3), (F1-F6) and (F4-F9) were elaborated to investigate the impact of surfactant type, amount of cholesterol and inclusion of 
lecithin on the various properties of the prepared formulations, respectively. 
 
In vitro release studies 
Release studies were carried out for both pure benazepril 
hydrochloride and the loaded niosomal formulations. Each 
Formulation was instilled in a dialysis membrane bag with a 
molecular weight cut off (8000-12 000 KDa) and sealed from both 
sides [9]. It was then tied to the shaft of dissolution apparatus 
(Vanguard/USA) and immersed in 500 ml of de-ionized water at 
constant temperature 37±0.5 °C and rotation speed of 50 rpm. 
Thereafter, Samples of 5 ml were taken at predetermined intervals 
and replaced with fresh media so that the sink condition is 
maintained. Percentage drug released was assayed using a UV-Vis 
spectrophotometer (Shimadzu, UV-Vis 1650, Japan) at 241 nm [10]. 
Studies were carried out in triplicate for each formulation and 
presented as the average±standard deviation (SD). 
Zeta potential (ζ potential) 
Zeta potential for all niosomal formulations was measured with 
zeta-sizer (Zeta Plus) (Brookhaven Instruments, USA) which has a 
sensitivity range from-150 to+150 millivolt (mV) and accuracy 
of±2%. It is equipped with 35 milliwatt (mW) solid state laser, red 
(660 nm wavelength) [11]. 
Transmission electron microscopy (TEM) 
A drop of diluted specimens of the optimized formulations F7 and F8 
was placed on the grid and then observed using CM 10 transmission 
electron microscope to confirm niosomes formation and examine 
their morphology. Samples were observed at an operating voltage of 
80 kilovolts (KV) [12]. 
Statistical analysis 
The obtained data were analyzed using the one-way analysis of 
variance (ANOVA) test. (P<0.05) was considered as an estimate of 
significance when evaluating the degree of differences between 
various formulations. 
RESULTS AND DISCUSSION 
Preparation of niosomes 
Based on the collected data, It has been concluded that the type of 
surfactant, amount of cholesterol and inclusion of soya lecithin are 
influential factors that governs the vesicle size, poly-dispersity, 
entrapment efficiency and in vitro release profile.  
Vesicles size and polydispersity index (PDI) 
The measured vesicles diameters of all niosomal formulations are 
listed in the table (2). The results reveal that when other variables 
were fixed, the stearyl chain (C18) surfactants (span 60 and brij 72) 
produced significantly (p<0.05) bigger vesicles than palmityl chain 
(C16) surfactant (span 40). This might be explained by the effect of 
the alkyl chain length. Longer alkyl chains produce wider bilayers; 
consequently, larger vesicles are attained. Similar findings were 
obtained with glimepiride niosomes [13]. 
The results also showed that increasing cholesterol content from 
100 mg to 400 mg led to lowering vesicles size significantly(p<0.05). 
The intercalation of cholesterol within the bilayers enhances their 
hydrophobic nature, thereby decreasing water uptake and 
decreasing both the aqueous core and vesicle size [14]. 
On the other hand, the addition of soya lecithin produced 
significantly larger vesicles (p<0.05) when comparing F7, F8 and F9 
with F4, F5and F6, respectively. Soya lecithin is a charge inducing 
agent that contains phosphatidylcholine as a major component. It 
imparts a negative charge on the surface of the vesicle allowing 
more water entrapment within the aqueous core. Therefore, larger 
vesicles are formed [15]. Polydispersity index (PDI) is considered a 
measure of the degree of the homogeneity in vesicle size distribution 
within the prepared formulations. PDI value below 0.3 is considered as 
an indication for monodisperse systems according to the literature 
[16]. The calculated PDI for the niosomal formulations ranged 
between 0.09 and 0.34. 
  
Table 2: Entrapment efficiency%, vesicle size, polysispersity and zeta potential of niosomal formulations 
Formulation  EE% Vesicle size±SD (micrometer)* PDI ζ potential(mV) 
F1 93.8 7.02±3.57 0.26 -39.14 
F2 90.4 4.57±2.337 0.26 -42.68 
F3 92.9 7.38±4.34 0.34 -12.22 
F4 86.8 5.01±2.1 0.17 -45.14 
F5 80.4 3.9±1.7 0.19 -35.03 
F6 84.7 5.241±2.6 0.24 -12.93 
F7 97.8 8.72±4.4 0.25 -32.13 
F8 94.4 6.21±2.5 0.16 -45.91 
F9 95.9 7.01±2.2 0.09 -20.12 
*(n=3) (mean±standard deviation) 
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Entrapment efficiency (EE %) 
The results of EE% (table 2) revealed that formulations F1 (span 60) 
and F3 (brij 72) gave higher (p<0.05) EE% than F2 (span 40). This 
may be ascribed to the entrapment of the hydrophilic drug 
(benazepril HCL) in the internal aqueous core of niosomes which is 
mainly affected by the length of the alkyl chain of the surfactant 
employed. These results are compatible with the vesicles diameters 
measurements where longer alkyl chain surfactants (span 60 and 
brij 72) produced bigger vesicles. As a result, provided more space 
for the trapped solute [17]. 
The increment of cholesterol content from 100 mg in (F1, F2 and F3) 
to 400 mg in (F4, F5 and F6) has led to significant lowering in EE% 
(p<0.05). This might be due to the decrease in volume diameter [18].  
The impact of charge inducing agent on EE% was investigated by the 
inclusion of 50 mg soya lecithin into formulations (F7, F8 and F9). As 
expected, EE% was enhanced significantly (p<0.05) in these 
formulation as a result of their relatively large vesicles which allows 
for more solute entrapment [19]. Besides, it might be due to the 
electrostatic attractions between the cationic drug and the 
negatively charged vesicles. Similar observations were obtained in 
tamoxifen citrate loaded span-based nanovesicles [20].  
In vitro release studies 
All formulations showed sustained release when compared to a pure 
drug which exhibited percent release of 99.9% within 15 min (fig. 1). 
This might be due to the inherent nature of niosomes as a depot that 
encapsulate the drug and releases it in a controlled manner. 
Formulations F1, F2 and F3 were elaborated using span 60, span 40 and 
brij 72, along with cholesterol in ratio of (4:1) to investigate the impact of 
surfactant structure on the release profile from niosomal formulations. 
The release profile followed the trend span 60<span 40<brij 72 where 
span 60 formulation exhibited the slowest release rate (p<0.05) among 
the other formulations. It has been previously reported that more tight 
and compact niosomes results from more hydrophobic span surfactants 
when hydrated in presence of cholesterol [21]. These findings agree with 
the previously reported results of paclitaxel niosomes [3]. 
Span 40 formulation exhibited a faster release rate (p<0.05) 
compared to span 60. This can be explained by the fact that span 40 
possess a shorter alkyl chain length and smaller vesicle diameter. 
Thus, a shorter diffusion path for benazepril HCL [22].  
Even though brij 72 share the same alkyl group (stearyl) chain with 
span 60, F3 showed significantly faster (p<0.05) release rate than 
F1. This may be attributed to the long hydrophilic polyoxyethylene 
head group in brij 72 which might build looser bilayered vesicles 
facilitating the drug escape [23]. 
  
 
Fig. 1: Benazepril HCl release from formulations (F1–F3) and pure drug (n=3) (mean±standard deviation) 
 
Increasing the amount of cholesterol from 100 mg in F1, F2 and F3 
to 400 mg in F4, F5 and F6 while fixing the quantities of surfactants 
led to a profound retardation effect(p<0.05) on the drug release rate 
as shown in (fig. 2). Cholesterol was employed in this study as a 
stabilizing agent that strengthens the cohesion and membrane 
rigidity. Therefore; it decreased drug permeability across the 
bilayered vesicles [24]. 
The inclusion of soya lecithin in F7, F8 and F9 also decreased the 
release rate significantly (p<0.05), as seen in (fig. 3) in terms of 
increasing membrane stability and reduced leakage [25]. 
 
 
Fig. 2: Benazepril HCl release from formulations (F1–F6) (n=3) (mean±standard deviation) 
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Fig. 3: Benazepril HCl release from formulations (F4–F9) (n=3) (mean±standard deviation) 
 
Formulations F7, F8 and F9 exhibited the desired sustained release 
profile as they released only 38.4%, 41.4% and 50.8% respectively 
at the end of 4 h. The least the drug released from the carrier 
vesicles, the higher encapsulated within to be absorbed at the 
absorption site in the gastrointestinal tract. 
Zeta potential (ζ potential)  
Zeta potential analyses provide a measure to the stability of colloidal 
dispersions. It governs the degree of repulsion of similarly charged 
particles, thereby preventing their flocculation. It is reported that 
zeta potential value of-30 to-60 mV is favourable for the niosomal 
stability, but if the potential is reduced below-30mV, the particles 
may attract each other and aggregate eventually [26]. 
Zeta potential measurements shown in the table (2) clearly suggest 
that formulations prepared using span 60 and span 40 possess 
adequate stability with potential range between-32.13 to-
45.91mV,whereas all formulations prepared using brij 72 had 
inadequate zeta potential range between-12.22 and-20.12 m V. 
Zeta potential measurements are directly related to the surface 
charge. Formulations (F1–F6) were prepared using non-ionic 
surfactants, yet they carry a negative charge due to adsorption of 
hydroxyl ions from aqueous medium [27]. 
Soya lecithin containing phosphatidylcholine as a major component 
was included in this study as a charge imparting agent to boost the 
niosomal stability. Obtained results revealed that addition of soya 
lecithin while fixing the quantities of both surfactant and cholesterol 
had increased the zeta potential from-35.03 in F5 to-45.91mV in F8 
and from-12.93 in F6 to-20.12 mV in F9. These findings are in 
agreement with clomipramine niosomes [28]. Fig. 4 depicts zeta 
potential analyses for F7 (A) and F8 (B) and F9 (C). 
Transmission electron microscopy (TEM) 
The obtained TEM images clearly elucidate the formation of 













Fig. 5: TEM micrograghs of F7 (A) and F8 (B) 
 
CONCLUSION 
It can be concluded that benazepril HCL was successfully formulated 
in niosomal formulations. Among all formulations, F7 and F8 
elaborated employing span 60 and span 40, respectively exhibit the 
desired properties with respect to size, PDI, EE%, ζ potential and in 
vitro release profile. Thus, they might be employed as potential 
carriers of benazepril HCL.  
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